Xbrane Biopharma

Xbrane Biopharma EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Xbrane Biopharma (XBRANE.ST) as of Oct 19, 2026 is -0.39. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was -1.44 — a change of -73.12% (higher).

EV/OCF

-0.39

YoY

-73.12%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Xbrane Biopharma is 2025 -0.39 . EV/OCF (Enterprise Value to Operating Cash Flow) of Xbrane Biopharma was 2024 -1.44 . It decreases by -73.12% higher compared to the previous year.

The Xbrane Biopharma EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2018
1.50 SEK
Jan 1, 2019
0.20 SEK
Jan 1, 2020
0.47 SEK
Jan 1, 2021
0.57 SEK
Jan 1, 2022
0.16 SEK
Jan 1, 2023
-0.72 SEK
Jan 1, 2024
-1.44 SEK
Jan 1, 2025
-0.39 SEK
The Xbrane Biopharma EV/OCF history
YEAREV/OCFYoY
-0.39-73.12%
-1.44+101.15%
-0.72-557.92%
0.16-72.58%
0.57+22.12%
0.47+136.77%
0.20-86.83%
1.50-146.58%
-3.22+32.49%
-2.43-77.37%
-10.74-77.87%
-48.53—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Xbrane Biopharma Stock analysis

What does Xbrane Biopharma do? Xbrane Biopharma AB, based in Solna, Sweden, operates in the Health Care sector as a biotechnology company specializing in the development and manufacturing of biosimilars. The company employs 92 full-time staff and focuses on injectable slow-release drugs and high-yield protein expression technology. Key products include Sperotide, a biosimilar to Decapeptyl, Trelstar, and Pamorelin, and Xlucane, a biosimilar to Lucentis, both developed for injectable use. Xbrane Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Xbrane Biopharma stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Xbrane Biopharma is -0.39 in 2025.

EV/OCF (Enterprise Value to Operating Cash Flow) of Xbrane Biopharma changed from -1.44 to -0.39, representing a -73.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Xbrane Biopharma since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Xbrane Biopharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Xbrane Biopharma

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Xbrane Biopharma